Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed Tests ...
"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...
Advanced lung cancer inflammation index (ALI) as a prognostic marker for locally advanced and metastatic cancer: A prospective study. Phase II study of disitamab vedotin (RC48) in combination with ...
Circulating tumor DNA (ctDNA), small pieces of DNA released from dying tumor cells into the bloodstream, can be easily and non-invasively identified and examined through a simple blood test. This ...
The FDA approved the Oncomine Dx Express Test for rapid identification of NSCLC patients eligible for Zegfrovy treatment. The test provides results in 24 hours, aiding timely therapeutic decisions and ...
NATICK, Mass., Nov. 12, 2025 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the launch of oncoReveal® Lymphoid, a research-use-only (RUO) next-generation ...
SKY92 and next-generation sequencing (NGS) of bone marrow tumour cells into routine patient care for the first time in Ireland ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback